Healthcare Services

Theranostics Market Outlook Driven by Key Growth Factors

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Theranostics Market Grow Between 2026 And 2030?

The theranostics market has experienced significant growth in recent years. This market is projected to expand from $122.98 billion in 2025 to $136.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. Historically, this expansion has been driven by advancements in molecular diagnostics, an increased prevalence of chronic diseases, the rise of oncology-focused research programs, the availability of targeted therapeutics, and the broadening of diagnostic laboratory infrastructure.

The theranostics market is poised for rapid expansion in the coming years, with its size projected to reach $205.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This growth during the forecast period is attributable to increasing investments in precision medicine, the growing adoption of AI-driven diagnostic tools, the broader application of theranostic techniques in oncology, greater integration of genomics into clinical practice, and an elevated demand for personalized treatment outcomes. Key trends expected over this period include the increasing integration of diagnostics with targeted therapies, a rising acceptance of personalized medicine platforms, the expanded use of molecular imaging techniques, the development of more companion diagnostics, and a heightened focus on patient-specific treatment pathways.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10823&type=smp

What Key Factors Are Affecting The Theranostics Market Demand?

The increasing occurrence of cancer is projected to fuel the expansion of the theranostics market moving forward. Cancer, characterized by uncontrolled cellular proliferation that affects various organs and leads to considerable illness and fatalities globally, presents a significant challenge. Theranostics, which combines diagnostic tools with therapeutic interventions, shows great promise in managing both cancer and chronic conditions. This method facilitates individualized and precise treatments through its integrated diagnostic and therapeutic abilities, opening avenues for advancements within the healthcare industry. Consequently, the growing number of individuals afflicted with cancer will contribute to the theranostics market’s progression. For example, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that 3 million people in the UK were living with cancer in 2024, a figure expected to climb to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the escalating prevalence of cancer is a key driver for the theranostics market.

What Are The Main Segments Within The Theranostics Market Segment Structure?

The theranostics market covered in this report is segmented –

1) By Disease Type: Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, Other Diseases

2) By Technology: Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, Other Technologies

3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Neurological Disorders: Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy

2) By Cardiovascular Diseases: Coronary Artery Disease, Heart Failure, Atrial Fibrillation, Hypertension

3) By Immunological Disorders: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Psoriasis

4) By Oncology Diseases: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

5) By Other Diseases: Infectious Diseases, Metabolic Disorders, Genetic Disorders

What Trends Are Influencing Changes In The Theranostics Market?

Leading companies in the theranostics market are focusing on developing advanced technological solutions, such as theranostics clinical trials, to improve personalized medicine and patient outcomes by integrating diagnostics and therapeutics into a unified treatment approach. Theranostics clinical trials are research studies that assess the combined application of diagnostic tests and targeted therapies to customize treatment strategies for individual patients. These trials aim to determine the effectiveness of specific treatments based on patient-specific biomarkers, thereby enhancing personalized medicine. For instance, in May 2024, BAMF Health, a US-based cancer treatment center, initiated the COMBAT Trial, officially titled “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). Key features of this trial include a rapid activation process through BAMF Health’s BAMF RapAct program, which allowed it to launch in just seven weeks, and a strong focus on utilizing innovative radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR), aiming to expand treatment options for patients with limited therapeutic avenues.

Who Are The Companies Participating In The Theranostics Market?

Major companies operating in the theranostics market are Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Radiopharm Theranostics Ltd, Alpha-Theranostics, Cardio-Theranostics LLC, Curium, Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Bristol-Myers Squibb Company, Danaher Corporation, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

Get The Full Theranostics Market Report:

https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report

Which Region Has The Greatest Market Share In The Theranostics Market?

North America was the largest region in the global theranostics market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Theranostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report

Browse Through More Reports Similar to the Global Theranostics Market 2026, By The Business Research Company

Radiopharmaceutical Theranostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-theranostics-global-market-report

Music Therapy Market Report

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Antidotes Market Report

https://www.thebusinessresearchcompany.com/report/antidotes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795